Vera Therapeutics Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy
Reuters
Nov 06
Vera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 3 Results for Atacicept in IgA Nephropathy
Vera Therapeutics Inc. announced positive results from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN). The data were presented as a late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 and simultaneously published in The New England Journal of Medicine. Atacicept met its primary endpoint, demonstrating a 46% reduction in proteinuria from baseline and a 42% reduction compared to placebo at week 36 (p<0.0001). The safety profile of atacicept was reported to be favorable and comparable to placebo. Vera Therapeutics plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration through the Accelerated Approval Program in the fourth quarter of 2025, with a potential PDUFA date in 2026. The ORIGIN 3 trial is ongoing, with two-year results expected in 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570239-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.